Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life (PICS)

January 31, 2024 updated by: Romain Ronfle

The goal of this observational study is to show the patient discomfort during their stay in intensive care is directly linked to the occurrence of a post ICU syndrome at 3 months.

The main questions it aims to answer are :

  • Evaluate the value of the IPREA score on quality of life impairment a 3 months ;
  • Identify the 3 areas of discomfort most associated with progression to a post ICU syndrome at 3 months ;
  • Define a threshold value for the IPREA score ;
  • Correlate clinical assessment and psychological follow-up with the to the prediction of a post ICU syndrome ;
  • Establish a correlation between IPREA score and time to first rise
  • Establish a correlation between identified factors of post ICU syndrome and IPREA score

Study Overview

Status

Completed

Detailed Description

A stay in intensive care can be seen as a stressful ordeal for a patient's body, both physically and morally. Among patients alive following a stay in intensive care, half have a disabling psychiatric disorder. The main psychiatric disorders described in post-resuscitation are anxiety, depression and post-traumatic stress disorder (PTSD). When one of these disorders is present, there is a 64% chance that it will coexist with one of the other two disorders. These psychological disorders will have an impact on the quality of life and mortality of patients leaving intensive care. Depression is independently associated with an increased risk of further hospitalisation. These different psychological and somatic disorders can be found in the same entity: post-resuscitation syndrome (PRS).

In a context where the proportion of awake patients is growing in our intensive care units, the impact of subjective factors is becoming increasingly important. A stay in intensive care is marked by a stressful environment for the patient at several levels, as well as by care procedures that are often experienced as traumatic (mechanical ventilation, dialysis and invasive procedures). For example, memories of terrifying experiences, often the source of nightmares or hallucinations that persist beyond the hospital stay, encourage the development of PTSD. Similarly, certain environmental factors such as lighting conditions and noise levels can have an impact on patient comfort during their stay in intensive care, confirming the importance of better controlling all external factors that can contribute to stress. Targeted measures centred on an isolated objective, such as reducing thirst, have shown real clinical benefit in terms of patient outcome. Recognition of these sources of discomfort in intensive care and resuscitation units is a first step towards optimising patient comfort. A research team have developed a standardised and validated discomfort score (Discomforts of Patients in Intensive Care, IPREA) that enables several discomforts perceived throughout the intensive care stay to be identified and quantified.

In addition to the psychiatric consequences, the investigators know that patients who survive a stay in intensive care face physical and cognitive consequences for their state of health. PRS is a concept that includes these three dimensions, defined as cognitive dysfunction, acquired physical weakness and altered mental health. It is thought to affect at least 50% of patients. The growing interest in this syndrome is explained by its multi-dimensional aspect, which is representative of patients' long-term quality of life. The potential impact between discomfort in intensive care and long-term psychiatric consequences, or more broadly the occurrence of an PRS, is a central question with an impact on our daily practice. In addition, a bedside assessment using simple tools as part of a psychological follow-up could help to prevent or at least recognise early the factors favouring an PRS.

Study Type

Observational

Enrollment (Actual)

175

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aix-en-Provence, France, 13100
        • Centre Hospitalier Intercommunal Aix-Pertuis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients admitted in ICU during minimum 3 days

Description

Inclusion Criteria:

  • Patient admitted to the intensive care unit at Aix-en-Provence hospital (sepsis, acute respiratory distress, disturbed consciousness, emergency surgery, etc.)
  • Minimum stay of 3 calendar days

Exclusion Criteria:

  • Patient under 18 years
  • Patients deprived of their liberty, under guardianship or trusteeship
  • Non-French-speaking patient
  • Presence of a pre-existing cognitive disorder as assessed by a clinician
  • Participation in an interventional research protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessing the impact of the overall discomfort of intensive care patients on the occurrence of a psychiatric RPD at 3 months
Time Frame: 3 months
Occurrence of discomfort in intensive care as defined by the IPREA score
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessing the value of the IPREA score in terms of quality of life at 3 months
Time Frame: 3 months
Relation between IPREA score and quality of life
3 months
Identifying the 3 areas of discomfort most associated with progression to post ICU syndrome at 3 months
Time Frame: 3 months
Relation between discomfort during hospitalization and post ICU syndrome
3 months
Defining a threshold value for the IPREA score
Time Frame: through study completion, an average of 1 year
Evaluation of IPREA score
through study completion, an average of 1 year
Correlation between clinical assessment and psychological follow-up with the post ICU syndrome
Time Frame: through study completion, an average of 1 year
Clinical experience of the clinician and the psychologist and the interest in predicting a post ICU syndrome
through study completion, an average of 1 year
Establish a correlation between IPREA score and time to first rise
Time Frame: through study completion, an average of 1 year
Evaluation of IPREA score
through study completion, an average of 1 year
Correlation between identified factors of post ICU syndrome and IPREA score
Time Frame: through study completion, an average of 1 year
Evaluation and relation between factors of post ICU syndrome and IPREA score
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Romain RONFLE, MD, Centre Hospitalier Intercommunal Aix-Pertuis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 8, 2022

Primary Completion (Actual)

October 14, 2023

Study Completion (Actual)

October 14, 2023

Study Registration Dates

First Submitted

January 15, 2024

First Submitted That Met QC Criteria

January 31, 2024

First Posted (Actual)

February 2, 2024

Study Record Updates

Last Update Posted (Actual)

February 2, 2024

Last Update Submitted That Met QC Criteria

January 31, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 20220205-7

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Subscribe